| 2025-04-17 10:59 | CC:MIR | Medmira Inc | 0.09 | News Release200 | Medmira forms Reveal G4 HIV partnership with Lovell |
| 2025-04-02 00:48 | CC:MIR | Medmira Inc | 0.10 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2025-04-02 00:48 | CC:MIR | Medmira Inc | 0.10 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2025-04-01 22:01 | CC:MIR | MedMira Inc. | 0.10 | News Release200 | MedMira Reports Second Quarter Results FY2025 |
| 2025-02-27 20:56 | CC:MIR | Medmira Inc | 0.115 | News Release200 | Medmira enters partnership with MediGroup |
| 2025-02-25 18:24 | CC:MIR | Medmira Inc | 0.12 | News Release200 | Medmira signs exclusive distribution deal with Trimedic |
| 2025-01-21 19:27 | CC:MIR | Medmira Inc | 0.13 | News Release200 | Medmira receives ITAs for Multiplo TP/HIV rapid tests |
| 2025-01-14 19:07 | CC:MIR | Medmira Inc | 0.12 | News Release200 | Medmira receives Health Canada OK for RevealRapid |
| 2025-01-09 18:31 | CC:MIR | Medmira Inc | 0.13 | News Release200 | Medmira receives Health Canada OK for Multiplo trials |
| 2024-12-30 22:00 | CC:MIR | MedMira Inc. | 0.105 | News Release200 | MedMira Reports First Quarter Results FY2025 |
| 2024-12-30 16:18 | CC:MIR | Medmira Inc | 0.105 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2024-12-30 16:18 | CC:MIR | Medmira Inc | 0.105 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2024-12-24 13:53 | CC:MIR | Medmira Inc | 0.085 | News Release200 | Medmira gets Health Canada OK for Multiplo TP/HIV test |
| 2024-12-24 12:16 | CC:MIR | MedMira Inc. | 0.075 | News Release200 | Canadian Investment Regulatory Organization Trade Resumption - MIR |
| 2024-12-24 12:05 | CC:MIR | Medmira Inc | 0.075 | Resume Trading385 | Medmira to resume at 9:30 a.m. PT |
| 2024-12-24 10:15 | CC:MIR | MedMira Inc. | 0.075 | News Release200 | Canadian Investment Regulatory Organization Trading Halt - MIR |
| 2024-12-24 10:10 | CC:MIR | Medmira Inc | 0.075 | Halt Trading170 | Medmira halted at 7:09 a.m. PT |
| 2024-11-28 23:21 | CC:MIR | Medmira Inc | 0.085 | SEDAR Audited Annual Financial Statements804 | SEDAR Audited Annual Financial Statements |
| 2024-11-28 23:10 | CC:MIR | Medmira Inc | 0.085 | SEDAR MD & A815 | SEDAR MD & A |
| 2024-11-28 23:02 | CC:MIR | MedMira Inc. | 0.085 | News Release200 | MedMira Reports FY2024 Fourth Quarter and Year End Financial Results |
| 2024-10-03 19:12 | CC:MIR | Medmira Inc | 0.085 | News Release200 | Medmira appoints Crenshaw VP, commercial operations |
| 2024-08-13 17:53 | CC:MIR | Medmira Inc | 0.09 | News Release200 | Medmira to proceed with Syphilis antibody trials |
| 2024-07-03 16:16 | CC:MIR | Medmira Inc | 0.075 | News Release200 | Medmira loses $603,093 in fiscal Q3 |
| 2024-07-03 00:39 | CC:MIR | Medmira Inc | 0.08 | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
| 2024-07-03 00:39 | CC:MIR | Medmira Inc | 0.08 | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
| 2024-07-02 23:56 | CC:MIR | Medmira Inc | 0.08 | News Release200 | Medmira loses $603,093 in Q3 fiscal 2024 |
| 2024-04-30 22:10 | CC:MIR | Medmira Inc | 0.085 | News Release200 | Medmira appoints Bell as VP, business development |